Tests baxdrostat with dapagliflozin in people with kidney disease and high blood pressure
Tests baxdrostat plus dapagliflozin in adults with kidney disease and high blood pressure.
Plain-language title generated from the registry record
Registry title: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
Key facts
- Where
- Buenos Aires, CABA, Ciudad Autónoma de Bs. As., Ciudad de Buenos Aires, Córdoba, La Plata, Lanus, Lanús Este, Mar del Plata, Rosario, San Nicolás, Santa Fe, Santiago del Estero, and Temperley, ArgentinaSee the 14 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic kidney disease and high blood pressure who already take an ACE inhibitor or an ARB at a stable, maximum tolerated dose.
- Age
- 18 years or older
- Sex
- All sexes and genders can join
- Disease stage
- Chronic kidney disease with eGFR 30-59 or 60-75 mL/min/1.73 m² plus a set level of protein in the urine (UACR or UPCR); history of high blood pressure with systolic pressure ≥ 130 mmHg at screening and ≥ 120 mmHg at randomisation
- Earlier treatment
- A stable and maximum tolerated dose of an ACEi or an ARB (not both) for at least 4 weeks before screening
- Biomarker or test result
- Blood potassium ≥ 3.0 and ≤ 4.8 mmol/L if eGFR is 45 or higher, or ≥ 3.0 and ≤ 4.5 mmol/L if eGFR is below 45
Main reasons for not taking part
- Systolic blood pressure > 180 mmHg or diastolic > 110 mmHg at screening
- Known high potassium (≥ 5.5 mmol/L) within 3 months, or serum sodium < 135 mmol/L
- Type 1 diabetes (with limited exceptions in the US and Japan), or uncontrolled type 2 diabetes with HbA1c > 10.5% (91 mmol/mol)
- Dialysis or acute kidney injury within 3 months, or a history of organ or bone marrow transplant
- Heart failure class IV, or recent stroke, acute coronary syndrome or heart failure hospitalisation within 3 months
Read by machine on 9 November 2026.
Where in Argentina
- Buenos AiresHospital not named in the registryTaking people
- CABAHospital not named in the registryNo longer taking part
- Ciudad Autónoma de Bs. As.Hospital not named in the registryTaking people
- Ciudad de Buenos AiresHospital not named in the registryTaking people
- CórdobaHospital not named in the registryNo longer taking part
- La PlataHospital not named in the registryTaking people
- LanusHospital not named in the registryTaking people
- Lanús EsteHospital not named in the registryTaking people
- Mar del PlataHospital not named in the registryTaking people
- RosarioHospital not named in the registryTaking people
- San NicolásHospital not named in the registryTaking people
- Santa FeHospital not named in the registryTaking people
- Santiago del EsteroHospital not named in the registryTaking people
- TemperleyHospital not named in the registryNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06742723EU 2023-506460-14-00
- Record updated
- 6 November 2026
- Original description
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressureRead full original descriptionShow less
A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants With Chronic Kidney Disease and High Blood Pressure
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
Inclusion: Participants of any sex and gender must be ≥ 18 years of age at the time of signing the informed consent; Participants with (a) or (b):; eGFR 30-59 mL/min/1.73 m² (local or central laboratory value) AND:; UACR ≥ 30 mg/g (3.39 mg/mmol) and < 500 mg/g (56.5 mg/mmol) (central laboratory value only), or; UACR ≥ 500 mg/g (56.5 mg/mmol) and ≤ 5000 mg/g (565 mg/mmol) (local or central laboratory value), or; UPCR ≥ 700 mg/g (79 mg/mmol) and ≤ 7000 mg/g (790 mg/mmol) (local laboratory value only); (b) eGFR 60-75 mL/min/1.73 m² (local or central laboratory value) AND:; UACR ≥ 500 mg/g (56.5 mg/mmol) ) and ≤ 5000 mg/g (565 mg/mmol) (local or central laboratory value), or; UPCR ≥ 700 mg/g (79 mg/mmol) and ≤ 7000 mg/g (790 mg/mmol) (local laboratory value only); [obsolete]; Participants with history of HTN and a SBP ≥ 130 mmHg (the most recent value within 4 weeks prior to screening or at the Screening Visit) and ≥ 120 mmHg at the Randomisation Visit; Stable and maximum tolerated dose of an ACEi or an ARB (not both) for at least 4 weeks prior to Screening Visit; Participants with:; Serum or plasma potassium ≥ 3.0 and ≤ 4.8 mmol/L if eGFR ≥ 45 mL/min/1.73 m2 (local or central laboratory values); Serum or plasma potassium ≥ 3.0 and ≤ 4.5 mmol/L if eGFR < 45 mL/min/1.73 m2 (local or central laboratory values).
Exclusion: For US only: patients with T1DM treated with SGLT2i for at least 4 months, without DKA during that period, and who have experience with ketone monitoring are eligible for inclusion; Known hyperkalaemia, defined as potassium of ≥ 5.5 mmol/L within 3 months at screening; Serum sodium < 135 mmol/L (central or local laboratory values obtained within 4 weeks prior to screening or at the Screening Visit); For Japan only: patients with T1DM treated with dapagliflozin 10 mg for at least 4 months, without DKA during the period of dapagliflozin treatment are eligible for inclusion; 5 Uncontrolled T2DM with HbA1c > 10.5% (> 91 mmol/mol) (central or local laboratory values obtained within 3 months prior to screening or at the Screening Visit); 6 New York Heart Association functional HF class IV at screening; 7 Stroke, transient ischaemic cerebral attack, valve implantation or valve replacement, carotid surgery, or carotid angioplasty, acute coronary syndrome, or hospitalisation for worsening heart failure within previous 3 months prior to randomisation; 8 Documented history of adrenal insufficiency; 9 Any dialysis (including for acute kidney injury) within 3 months prior to Screening Visit; 10 Any acute kidney injury within 3 months prior to the Screening Visit; 11 History of organ transplant or bone marrow transplant, or planned organ transplant within 6 months following randomisation (including kidney transplant); 12 Any clinical condition requiring systemic immunosuppression therapy other than maintenance therapy (stable for at least 3 months prior to Visit 1); Systolic blood pressure > 180 mmHg, or diastolic BP > 110 mmHg at screening; Participants with T1DM will be excluded, except:.